home All News open_in_new Full Article

Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial

TUS+VEN+AZA triplet has potential as frontline therapy to treat large, mutationally diverse populations of AML SAN DIEGO and TORONTO, Jan. 09, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company, today announced dosing the first set of patients in the TUSCANY Phase 1/2 study […]


today 12 hours ago attach_file Science
attach_file Other
attach_file Politics
attach_file Society
attach_file Economics
attach_file Sport
attach_file Events
attach_file Culture
attach_file Technology
attach_file Science
attach_file Other
attach_file Politics
attach_file Society
attach_file Economics
attach_file Sport
attach_file Culture
attach_file Other
attach_file Politics
attach_file Society
attach_file Economics
attach_file Culture
attach_file Other
attach_file Politics
attach_file Economics
attach_file Culture
attach_file Other
attach_file Politics
attach_file Economics
attach_file Culture
attach_file Other
attach_file Politics
attach_file Economics
attach_file Other
attach_file Politics
attach_file Economics
attach_file Politics
attach_file Economics


ID: 15695310
Add Watch Country

arrow_drop_down